Bunschoten, C., Jacobs, B. C., Van den Bergh, P. Y. K., Cornblath, D. R. & van Doorn, P. A. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 18, 784–794 (2019).
Article CAS PubMed Google Scholar
Lünemann, J. D. Getting specific: targeting Fc receptors in myasthenia gravis. Nat. Rev. Neurol. 17, 597–598 (2021).
Allen, J. A. et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 23, 1013–1024 (2024).
Article CAS PubMed Google Scholar
Hansen, R. J. & Balthasar, J. P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88, 898–899 (2002).
Article CAS PubMed Google Scholar
Lünemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80–89 (2015).
Tackenberg, B. et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788–4792 (2009).
Article CAS PubMed PubMed Central Google Scholar
Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475, 110–113 (2011).
Article CAS PubMed PubMed Central Google Scholar
Quast, I., Cueni, F., Nimmerjahn, F., Tackenberg, B. & Lünemann, J. D. Deregulated Fcγ receptor expression in patients with CIDP. Neurol. Neuroimmunol. Neuroinflamm. 2, e148 (2015).
Article PubMed PubMed Central Google Scholar
Nelke, C., Spatola, M., Schroeter, C. B., Wiendl, H. & Lünemann, J. D. Neonatal Fc receptor-targeted therapies in neurology. Neurotherapeutics 19, 729–740 (2022).
Article CAS PubMed PubMed Central Google Scholar
Querol, L. A. et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics 19, 864–873 (2022).
Comments (0)